Clinical Application Value of Compound Kushen Injection Combined with Radiotherapy in Elderly Patients with Advanced Esophageal Cancer
Objective:To analyze the clinical application value of compound Kushen injection combined with radiotherapy in elderly patients with advanced esophageal cancer.Methods:A total of 70 elderly patients with advanced esophageal cancer treated in a hospital from March 2020 to March 2023 were selected and assigned to the control group and observation group by random number table,with 35 patients in each group.The control group was treated with radiotherapy,and the observation group was treated with compound Kushen injection in addition to the treatment given in the control group.The clinical efficacy,levels of T lymphocyte subsets(CD3+,CD4+,CD8+),levels of serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 50(CA50),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199),squamous cell carcinoma antigen(SCCA)],proportion of T helper cell 17(Th17),interleukin-17(IL-17)level,quality of life score and incidence of adverse reactions were compared between the two groups.Results:The disease control rate in the observation group(74.29% )was higher than that in the control group(51.43%,P<0.05).After treatment,CD3+and CD4+in both groups were increased,with the observation group showing higher levels than the control group,while CD8+,CEA,CA50,CA125,CA199,SCCA,proportion of Th17,IL-17 level and quality of life score were all decreased,with the observation group showing lower levels than the control group(P<0.05).During the treatment,the total incidence of adverse reactions in the observation group(17.14% )was lower than that in the control group(40.00%,P<0.05).Conclusion:Compound Kushen injection combined with radiotherapy can improve the clinical efficacy and quality of life in elderly patients with advanced esophageal cancer,improve immune function,down-regulate the expression of tumor markers,and reduce the incidence of adverse reactions.
万方数据
维普
